Massive Shrimp Recall: Nearly 45,000 Pounds Affected Over Dangerous Listeria Risk
The frozen product was distributed directly to distributors and retailers in California, Oregon, Washington, and British Columbia in Canada. Per the FDA, the product may have been further distributed and sold at retailers nationwide.
The recalled item is packaged in 1- and 5-pound plastic bags under the Bornstein Seafoods brand. The lot code is printed in the lower-left corner of the master case labels and at the bottom on the backs of the bags.
The affected 1-pound bags of shrimp meat have the UPC code 614133200246 and lot numbers A19008, A19009, A19019, A19026, A19030, A19032, A19037, and A19039. The affected 5-pound bags have the UPC code 614133200239 and lot numbers A19009, P11710, A18989, A19006, A19007, P11709, and P11710.
During routine sampling, listeria was detected in an in-process shrimp sample in the food production environment. Bornstein Seafoods has stopped distributing the product as it investigates what caused the problem.
Listeria monocytogenes is an organism that can cause serious and sometimes fatal infections in young children, elderly people, and others with weakened immune systems. According to the U.S. Centers for Disease Control and Prevention (CDC), symptoms of an intestinal illness caused by listeria typically include diarrhea and vomiting. Symptoms usually start within 24 hours after consuming the contaminated food and last one to three days.
If the bacteria has spread beyond the gut, people may experience more serious symptoms such as high fever, severe headache, stiffness, muscle aches, and fatigue. Symptoms of this type of illness usually start within two weeks after eating the contaminated food.
If you have a fever and other symptoms of listeriosis, such as fatigue and muscle aches, contact your healthcare provider immediately. So far, no illnesses have been reported due to the recalled product.
If you purchased the recalled product, return it to the place of purchase for a full refund. Consumers with questions may contact Bornstein Seafoods by emailing Andrew@bornstein.com.
Read the original article on Martha Stewart
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Miami Herald
43 minutes ago
- Miami Herald
Oswaldo Muñoz, pioneer of Venezuelan community in Miami, dies after long illness
Oswaldo Muñoz, entrepreneur, editor, community leader and a key figure in the history of the Venezuelan diaspora in the United States, died on July 25 in Madrid at the age of 73 after a long battle with cancer. Founder of the community newspaper El Venezolano and later of El Venezolano TV, both based in Miami, Muñoz was a beloved and visionary figure who helped weave the first threads of unity among Venezuelans in South Florida, back when they were just beginning to arrive in the city in the early 1990s. He died as he lived: discreetly, surrounded by the love of those closest to him, and faithful to his nature of shielding others from his own suffering. 'He didn't want anyone to know what he was going through,' said Ignacio Marcano, one of his closest companions during his final days. 'He would tell people he was just getting some tests done. He never wanted to worry anyone.' After Muñoz's final hospital visit, his doctors decided to sedate him. He passed away peacefully at 7 am local time in Madrid. Pioneer in unknown territory Oswaldo arrived in Miami in 1991, at a time when the Venezuelan community was so small that, as he liked to say, 'we could all fit in a restaurant dining room.' He founded El Venezolano in August 1992, just days after the devastating impact of Hurricane Andrew on South Florida. Against all odds, he managed to distribute the first edition amid the hurricane's devastation. From then on, El Venezolano became a beacon for thousands of newly arrived Venezuelans seeking news, guidance and a voice to represent them in exile. What began as a modest entrepreneurial venture turned into an influential media outlet with franchises in other U.S. cities and across Latin America. 'Oswaldo was the Venezuelan who brought Venezuelans and the local Miami community together the most,' said José Hernández, a friend and colleague who led the editorial team at El Venezolano for years. 'He was one of the first visible leaders at a time when there were hardly any Venezuelans in the city. He shared spaces with figures like Jorge Mas Canosa and other important community leaders.' More than just a paper For years, El Venezolano served as an extension of the Venezuelan consulate, especially when the official representation ceased operating in Miami. 'On many occasions, we functioned as the consulate,' recalls Sylvia Bello, Muñoz's business partner, friend and colleague for 25 years. 'Oswaldo was a man who supported so many people in every way.' The paper became a platform for employment, integration and gathering. 'He gave work to a lot of people,' Bello said. 'He organized events that brought together hundreds. At our anniversary editions, we hosted as many as 600 people in Miami's most prestigious hotels. Those were celebrations that showcased the strength and pride of our community.' Between 1998 and the years leading up to the COVID-19 pandemic, El Venezolano was an undisputed reference point—not only for its content but also for the approachable and charismatic style of its founder. Muñoz had a natural ability to connect with public figures and celebrities, his colleagues said. 'He was friends with everyone: El Puma (José Luis Rodríguez), the Stefans (Gloria and Emilio), you name it. He wasn't afraid of anything. He'd pick up the phone and everyone would answer,' Bello recalled. Those who knew him agree that behind the editor was a deeply generous person, always ready to help. 'He was the friend everyone wants to have—unconditional, compassionate, always smiling,' Bello added. For many immigrants arriving without support networks, without jobs, and without any idea of how to begin anew in a foreign city, Oswaldo was a guide and anchor. 'There was no one who approached him for help and didn't receive it,' Hernández said. 'In a way, he helped the city grow. Many people advertised with him, and many businesses started thanks to El Venezolano.' In a story he proudly shared, Oswaldo recounted meeting Nobel-prize winning novelist Gabriel García Márquez at a book fair in Bogotá. The Colombian writer complimented his writing. Oswaldo humbly replied that he wasn't a journalist by profession. García Márquez responded: 'You're wrong. Journalism is a craft, not a profession.' Few lines could have better described Muñoz's path. Without a university degree in journalism, he built a career based on vocation, instinct, empathy and an ability to connect with people. Enduring legacy Muñoz's legacy cannot be measured solely in printed issues or TV broadcasts. His greatest contribution, those close to him said, is the community he helped build. 'He fulfilled all his dreams,' says Sylvia Bello. 'Now he's in a better place, and he left a mark on each of us who knew him.' Over the last three years, Oswaldo waged a tough battle with cancer. It started in his spine, then moved to his lungs. Later, doctors needed to remove a kidney. Despite everything, he managed to recover multiple times. 'He always had this amazing ability to bounce back. I don't know how he did it,' Bello says. 'But eventually, his body said, 'This is it.'' Despite his deteriorating health, he tried to maintain life as normal as possible, those close to him said. Muñoz leaves behind a grateful community, dozens of friends, former coworkers, readers, and partners who considered him family, his friends said. He also leaves behind a body of work that will live on through the pages of El Venezolano and in the memories of those whose lives he touched. He was, in the words of those who knew and admired him, 'the unconditional friend everyone hopes to have,' perhaps the best headline to remember his life by.
Yahoo
an hour ago
- Yahoo
InflaRx Discontinues Pyoderma Gangrenosum Trial, Shifts Focus to INF904 with Summer 2025 Data Expected
InflaRx (NASDAQ:IFRX) is one of the best penny stocks under $1 to buy now. As May came to an end, InflaRx announced that its Phase 3 trial for vilobelimab in pyoderma gangrenosum/PG would be discontinued due to futility. The recommendation came from the Independent Data Monitoring Committee/IDMC after an unblinded interim analysis of data from the first 30 enrolled patients. The IDMC noted no unexpected adverse events. Following the recommendation, InflaRx intends to halt further development of vilobelimab for the PG indication. The company will now re-prioritize its resources on INF904, which is an orally administered small molecule inhibitor of C5a-induced signaling via the C5a receptor. Topline Phase 2a data readouts for INF904 in chronic spontaneous urticaria/CSU and hidradenitis suppurativa/HS are anticipated in the summer of 2025. A technician carefully measuring the quality of a nutritional supplement. GOHIBIC (vilobelimab) remains available in the US under an Emergency Use Authorization/EUA granted by the FDA. The authorization is for the treatment of COVID-19 in hospitalized adults when initiated within 48 hours of receiving invasive mechanical ventilation/IMV or extracorporeal membrane oxygenation/ECMO. Vilobelimab is a first-in-class, intravenously delivered, anti-C5a monoclonal antibody that selectively blocks free C5a, which is a potent inflammatory mediator. InflaRx (NASDAQ:IFRX) is a clinical-stage biopharmaceutical company that discovers and develops inhibitors using C5a technology in Germany and the US. While we acknowledge the potential of IFRX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Bayer Provides Regulatory Update on Elinzanetant for the Treatment of Moderate to Severe Hot Flashes Due to Menopause
WHIPPANY, N.J., July 25, 2025--(BUSINESS WIRE)--Bayer today announced that the U.S. Food and Drug Administration (FDA) has extended the review period for the New Drug Application (NDA) for elinzanetant. Elinzanetant is the first neurokinin 1 and neurokinin 3 receptor antagonist in late-stage clinical development for the hormone-free treatment of moderate to severe vasomotor symptoms (VMS) due to menopause. The FDA has determined additional time is needed for a full review of the NDA submission, including information provided to support the application. The extension to the Prescription Drug User Fee Act (PDUFA) review period is up to 90 days. The FDA did not raise any concern regarding the general approvability of elinzanetant in its correspondence. "We are confident in the potential of elinzanetant to provide meaningful clinical benefit to women pending regulatory approval," said Yesmean Wahdan, M.D., Senior Vice President and Head of Medical Affairs, North America, Pharmaceuticals. "We continue to work with the FDA to make this treatment available for women in menopause with moderate to severe hot flashes. Despite the universal experience of menopause, social stigma and misinformation persist, leaving many women to suffer without treatment and support. It's critical we advance innovation and education in menopause so women can work with their healthcare provider to determine the best option for them." The NDA is based on the positive results from the OASIS 1, 2 and 3 Phase III studies evaluating the efficacy and safety of the investigational compound elinzanetant versus placebo. Results from OASIS 1 and 2 were published in August 2024 in The Journal of the American Medical Association (JAMA). Detailed results of the Phase III study OASIS 3 providing supporting efficacy and additional long-term safety data were presented at The Menopause Society (TMS) annual meeting in September 2024. In the last 30 days, elinzanetant was approved under the brand name Lynkuet™ in the United Kingdom and Canada. Submissions for marketing authorizations for elinzanetant are also ongoing in the EU and other markets around the world. About Women's Healthcare at BayerWomen's Health is in Bayer's DNA. As a global leader in women's healthcare, Bayer has a long-standing commitment to delivering science for a better life by advancing a portfolio of innovative treatments. Bayer offers a wide range of effective short- and long-acting birth control methods as well as therapies for menopause management and gynecological diseases. Bayer is also focusing on innovative options to address the unmet medical needs of women worldwide and to broadening treatment choices such as in menopause. Additionally, Bayer intends to provide 100 million women per year in low- and middle- income countries by 2030 with access to family planning by funding multi-stakeholder aid programs for capacity building and by ensuring the supply of affordable modern contraceptives. This is part of the comprehensive sustainability measures and commitments from 2020 onwards and in line with the Sustainable Development Goals of the United Nations. About BayerBayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, "Health for all, Hunger for none," the company's products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2024, the Group employed around 93,000 people and had sales of 46.6 billion euros. R&D expenses before special items amounted to 6.2 billion euros. For more information, go to Find more information at Follow us on Facebook: Follow us on X: @BayerPharma Forward-Looking StatementsThis release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments. View source version on Contacts Media Contact: Colleen Murphy+1 Sign in to access your portfolio
